RxDoctor Payments Data

Kimberly Dalal, MD

Surgical Oncology · Burlingame, CANPI 1831168368

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $546 of the $691 with a category attached, or 79.0%. 5 manufacturers reported payments, led by Intuitive Surgical at 56.4% of the total. Reporting peaked in 2019 at $508 and has fallen 95.9% since, to $21 in 2024. That places this record below the midpoint for surgical oncology clinicians in CA, where the typical reported total is $1,777.

$691in general payments, 2019–2025

Across 13 payments — averaging $53.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$390
  • Davol Inc.$138
  • AbbVie$119
  • Merck$24
  • Johnson & Johnson$21
$8,000in research payments, 2019–2025

Across 1 payment — averaging $8000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Angiodynamics, Inc.$8K

What the payments were for

  • Food & beverage$54679%
  • Education$14521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical5$390
Davol Inc.4$138
AbbVie2$119
Merck1$24
Johnson & Johnson1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$691 in reported general payments places this provider in the 35th percentile of 209 surgical oncology providers in California.

See all surgical oncology providers in California

Medicare billing

Part B allowed, 2024
$173,752
Medicare patients
249
Services billed
638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase51$88,534
Pantoprazole Sodium25$170
Sucralfate12$94
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$119$88,53451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 209 surgical oncology providers in California.

Other surgical oncology in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →